- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06005766
The Efficacy of Metacognitive Skills Training in the Context of Forensic Psychiatric Care
Does Group-Based Metacognitive Skills Training Reduce Jumping to Conclusions Bias of Patients With Psychotic Disorders in the Context of Forensic Psychiatric Care
Deficiencies in social cognition are part of the core symptomatology of psychotic disorders. And deficiencies in social cognition, the closely related concept of metacognition, and, for example, paranoid attitudes are all associated with violence. The link between social cognition and violence is also observed through rehabilitation, as both group-based Social Cognition Interaction Training (SCIT) and group-based Metacognitive Skills Training (MCT) have reduced violent behavior in patients with psychotic disorders. Thus, a better knowledge of social cognition and its rehabilitation in psychotic disorders can help to reduce risky behavior and to rehabilitate the significant social difficulties often found in psychotic disorders. This research study aims to examine factors underlying the efficacy of group-based MCT.
The goal of the metacognitive skills training group developed by Moritz and partners is to strengthen the social and metacognitive skills of the patients participating in the group. The group consists of 10 sessions during which exercises and discussion are emphasized. The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory. Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/). Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions. Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning. As delusionality is related to the risk of violence, these results form a logical link between jumping to conclusions, delusionality, and violence.
But the results regarding the effectiveness of MCT are still somewhat conflicting, and studies seem to be of varying quality. Additional longitudinal research and research related to the jumping to conclusion bias are also needed. The hypothesis regarding this study is that the MCT group reduces patients' tendency to jump to conclusions. These reductions are presumed to be associated in one-year follow-up with fewer mood symptoms, delusions, paranoia, and more psychological flexibility.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Based on their multi-professional treatment plan in the Vanha Vaasa hospital, participation in the MCT group intervention is offered to patients who could benefit from it. The intervention under investigation is part of the standard care of the hospital. Participation does not prevent participation in other forms of rehabilitation, and patients can participate in the group even if they don't participate in the study. Being part of the control group does not prevent participation in the intervention group, but being part of the control group might delay participation. When these are in conflict, treatment takes precedence over research.
Data is collected until the sample size is satisfactory (at least 20 to 25 patients). Patients in the MCT condition are compared to patients (n=30) and controls (n=30) measured with a psychological test battery not completing the group. The test battery is the same for all the groups. It consists of valid tasks measuring neurocognition, social cognition, and psychiatric symptoms and a task for measuring the tendency to jump to conclusions. Patients in the group condition are tested before the group and nine months after the group has concluded. For both control groups testing interval is one year.
The comparison between the groups (intervention group, patient controls, and non-patient controls) is done by comparing the rate of change in the tendency to jump to conclusions. This comparison is done with regression analysis. If minor differences and equal variances are assumed (delta of slope 0.1), the power of the comparison is around 0.57. If larger differences are assumed (delta of slope 0.5), the power of the comparison approaches 1. In a previous study, a medium-sized comparative difference between patients in MCT condition and patients in cognitive remediation condition was found.
To avoid problems with multiple testing, the differences in magnitudes of mood symptoms, delusions, paranoia, and psychological flexibility after the delay are assessed with MANOVA. In a recent meta-analysis, the observed effect of MCT on delusions was high medium (g=0.69). The observed effect on negative symptoms was small but significant (g=0.23). Consequently, the expected power of the MANOVA ranges from 0.48 to 0.99. Direct comparisons are made with discriminant analysis with identical power estimates. Univariate ANOVAs can also be used, but with much worse power estimates, when controlling for multiple testing.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Leo Kuutti, MA
- Phone Number: +358 029 524 3058
- Email: leo.kuutti@vvs.fi
Study Contact Backup
- Name: Alice Keski-Valkama, PhD
- Phone Number: +358 029 524 3055
- Email: Alice.keski-valkama@vvs.fi
Study Locations
-
-
-
Vaasa, Finland
- Recruiting
- Vanha Vaasa Hospital
-
Contact:
- Leo Kuutti
- Phone Number: +358295243058
- Email: leo.kuutti@vvs.fi
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria (patients):
- Willingness to participate in a scientific study
- Diagnosis of a psychosis spectrum disorder
- Finnish language skills due to questionnaires and psychological tests being in Finnish
Exclusion Criteria (patients):
- Psychosis that severely deteriorates the ability to function
- Cognitive problems that severely deteriorate the ability to function
- Guardianship established for personal matters
Inclusion Criteria (non-patient controls):
- Willingness to participate in a scientific study
- Self-assessed sufficient Finnish language skills due to questionnaires and psychological tests being in Finnish
Exclusion Criteria (non-patient controls):
- Diagnosis of a psychosis spectrum disorder
- Cognitive problems that severely interferes with functioning
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention group
Patients with a psychosis spectrum disorder participating in the group-based metacognitive skills training and receiving treatment as usual
|
The goal of the metacognitive skills training group developed by Moritz and co. is to strengthen the social and metacognitive skills of the patients participating in the group.
The group consists of 10 sessions during which exercises and discussion are emphasized.
The themes of the group sessions are, for example, jumping to conclusions -bias, empathy, and memory.
Detailed information is available from the MCT website (https://clinical-neuropsychology.de/metacognitive_training-psychosis/).
Overall there is meta-analysis-level evidence for the moderate effectiveness of MCT on positive symptoms of psychotic illnesses, such as delusions.
Prior studies have argued that the unique factor underpinning MCT's efficacy is its impact on various cognitive biases, and that participating in the group especially reduces patients' tendency to jump to conclusions, which is a cognitive style associated with delusions and deficits in social perception and reasoning.
Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
|
|
Active Comparator: Patient controls
Patients with a psychosis spectrum disorder receiving standard long-term care in the hospital
|
Medicinal treatment deemed appropriate by the attending physician, psychiatric ward treatment, and others forms of treatment recommended to the patients based on their treatment plans (e.g., work therapy, dialectical behavior therapy, talk therapy)
|
|
No Intervention: Non-patient controls
Control group consisting of test subjects without a diagnosis of psychosis spectrum disorder
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Jumping to conclusions bias
Time Frame: For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
The bias is measured using a revised version of the beads task.
This is a test of optimal performance, meaning that both low and high scores can be problematic.
|
For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Paranoia and psychotic experiences
Time Frame: For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
Paranoia and psychotic experiences assessed with the Symptoms Checklist 90 self-report questionnaire.
The scale for paranoia goes from 0 to 24 with higher scores meaning worse outcome.
The scale for psychotic experiences goes from 0 to 40 with higher scores meaning worse outcome
|
For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
|
Mood symptoms
Time Frame: For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
Mood symptoms assessed with Symptoms Checklist 90 self-report questionnaire.
The sum for scales measuring depression and anxiety goes from 0 to 92 with higher scores meaning worse outcome.
|
For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
|
Psychological flexibility
Time Frame: For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
Psychological flexibility assessed with the the comprehensive assessment of acceptance and commitment therapy processes - Short Form (CompACT-8) self-report questionnaire.
The total CompACT score ranges from 0-48, with higher scores indicating greater psychological flexibility: The ability to attend and adapt to situational demands in the pursuit of personally-meaningful longer-term goals.
|
For the intervention group, the measurement is done before the group and nine months after completion. For the control groups, the time interval is one year.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Raimo Lappalainen, PhD, University of Jyväskylä
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VVSJYUMCT01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychotic Disorders
-
Medical College of WisconsinCompletedSchizophrenia | Affective Disorders | Psychotic Disorder | Psychotic Mood Disorder
-
Søren Dinesen ØstergaardCompletedAffective Disorders, PsychoticDenmark
-
University Hospital, CaenRecruiting
-
Instituto de Investigación Hospital Universitario...Carlos III Health Institute; European Regional Development FundCompletedSchizophrenia and Disorders With Psychotic Features | Psychotic EpisodeSpain
-
Philipp HomanRecruitingPsychotic DisorderCzechia, Ireland, Netherlands, Norway, Switzerland, Turkey (Türkiye)
-
Centre hospitalier de Ville-Evrard, FranceRecruiting
-
Instituto de Investigación Hospital Universitario...CompletedSchizophrenia and Disorders With Psychotic Feature | Psychotic EpisodeSpain
-
University Hospital, Strasbourg, FranceRecruiting
-
University of California, San DiegoCompletedSchizophrenia | Schizoaffective Disorder | Mood Disorder, PsychoticUnited States
-
University of MinnesotaUniversity of California, San FranciscoCompletedPsychotic Disorders | Schizophrenia | Schizoaffective Disorder | Cognitive Impairment | Psychosis | Treatment | Psychotic Depression | Psychotic Episode | Active Control | Psychotic Mood DisordersUnited States
Clinical Trials on Metacognitive Skills Training (MCT)
-
ZI-YU LINCompletedSchizophrenia | Bipolar Disorder | Major Depressive DisorderTaiwan
-
University Hospital, Strasbourg, FranceNot yet recruitingSchizophrenia Spectrum Disorder
-
Instituto de Investigación Sanitaria de la Fundación...Universidad Autonoma de MadridUnknownSchizophrenia Spectrum and Other Psychotic DisordersSpain
-
Universitätsklinikum Hamburg-EppendorfCompleted
-
Universitat Autonoma de BarcelonaHospital Son Espases; Parc Sanitari Sant Joan de Déu; Andaluz Health Service; Hospital... and other collaboratorsRecruitingSchizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders | Schizoaffective Disorder | Delusional Disorder | Schizophreniform Disorders | Brief Psychotic DisorderSpain
-
University of British ColumbiaVancouver Coastal Health Research Institute; Vancouver General Hospital; Vancouver... and other collaboratorsTerminatedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | PsychosisCanada
-
Fundació Sant Joan de DéuParc Sanitari Sant Joan de Déu; Solidaritat Sant Joan de Déu; FluidraRecruiting
-
University of Sao PauloActive, not recruiting
-
University of GaziantepNot yet recruitingObsessive-Compulsive Disorder
-
Sormland County Council, SwedenUppsala County Council, Sweden; Västmanland County Council, SwedenRecruiting